Clinicopathological and genomic features of extrachromosomal DNA in gastric cancer [0.03%]
胃癌中外显体DNA的临床病理和基因组特征
Yukio Hokazono,Mihoko Saito-Adachi,Natsuko Hama et al.
Yukio Hokazono et al.
Background: Extrachromosomal DNA (ecDNA), a form of circular DNA located outside chromosomes, is a common driver of oncogene amplification. Recent pan-cancer studies have associated ecDNA with cancer progression and poor ...
A gene-expression signature defines a subtype of Stomach Adenocarcinomas with low levels of Claudins and a high ratio of NF-YA long/NF-YA short splicing variants [0.03%]
一种基因表达谱型定义了一种Claudins低水平和NF-YA长/短剪切变异体比例较高的胃腺癌亚型
Alberto Gallo,Mirko Ronzio,Maria Barbara Campbell et al.
Alberto Gallo et al.
Background: Claudin-3, Claudin-4, and Claudin-7 are expressed on the surface of epithelial cells. Their absence in neoplastic cells of epithelial origin is an aggressiveness marker in different cancers. The NF-YA gene cod...
Clinical utility impact of DNA-based cytology using droplet digital methylation-specific PCR in gastric cancer [0.03%]
基于DNA的细胞学在胃癌中使用液滴数字化甲基化特异性PCR的临床效用影响
Hiroki Harada,Takafumi Soeno,Akira Ooki et al.
Hiroki Harada et al.
Background: Peritoneal dissemination is a major cause of poor prognosis in gastric cancer (GC). Although conventional peritoneal lavage cytology (CY) is used to detect micrometastatic peritoneal spread, its sensitivity is...
Health-related quality-of-life outcomes with regorafenib in advanced gastric and esophagogastric junction cancer: results from the INTEGRATE trials [0.03%]
REGORAFENIB治疗晚期胃及胃食管交界处癌的健康相关生活质量结果：INTEGRATE试验结果
Andrew J Martin,Yu Yang Soon,Katrin Marie Sjoquist et al.
Andrew J Martin et al.
Background: The INTEGRATE trials evaluated regorafenib in advanced gastric and esophagogastric junction cancer (AGOC), a poor prognosis population. In INTEGRATE 1 (I1, phase 2), regorafenib improved progression-free survi...
Comparative efficacy and safety of tislelizumab and other programmed cell death protein 1 inhibitors in first-line treatment of advanced gastroesophageal cancers: a systematic review and network meta-analysis [0.03%]
替雷利珠单抗和其他程序性死亡蛋白1抑制剂一线治疗晚期胃食管癌疗效和安全性的比较：系统评价和网状Meta分析
Jaffer A Ajani,Maria Alsina,Markus Moehler et al.
Jaffer A Ajani et al.
Background: Several programmed cell death protein-1 inhibitors are approved for the first-line treatment of advanced gastric/gastroesophageal junction cancer, including pembrolizumab, nivolumab and, more recently, tisleli...
COPS5 inhibition synergizes with the antitumor effect of trastuzumab by PTEN upregulation in HER2-amplified gastric cancer [0.03%]
COPS5抑制通过增加PTEN的表达与曲妥珠单抗协同抵抗HER2扩增胃癌的作用
Sung-Hyun Hwang,Ji-Won Kim,Haeseong Park et al.
Sung-Hyun Hwang et al.
Background: COP9 Signalosome Subunit 5 (COPS5) is a deubiquitinating enzyme that induces chemotherapy resistance. The role of COPS5 amplification in patients with gastric cancer (GC) and its therapeutic potential in HER2-...
COPS5 inhibition synergizes with the antitumor effect of trastuzumab by PTEN upregulation in HER2-amplified gastric cancer [0.03%]
COPS5抑制通过增加PTEN的表达与曲妥珠单抗联合用药可协同增强HER2扩增胃癌的抗肿瘤作用
Sung-Hyun Hwang,Ji-Won Kim,Haeseong Park et al.
Sung-Hyun Hwang et al.
Background: COP9 Signalosome Subunit 5 (COPS5) is a deubiquitinating enzyme that induces chemotherapy resistance. The role of COPS5 amplification in patients with gastric cancer (GC) and its therapeutic potential in HER2-...
Dynamic postoperative prognosis and follow-up optimization for gastric cancer patients after neoadjuvant therapy: a multicenter retrospective study [0.03%]
新辅助治疗后胃癌患者术后预后评估及随访策略的优化多中心回顾性研究
Qing Zhong,Zhi-Quan Zhang,Kai-Ning Ye et al.
Qing Zhong et al.
Background: Conditional survival (CS) estimates the probability of future survival based on time already survived. However, evidence regarding postoperative dynamic follow-up in gastric cancer patients after neoadjuvant t...
Gallbladder edema as a clue to zolbetuximab-associated protein-losing enteropathy in gastric cancer: a case report [0.03%]
一例胃癌佐贝妥珠单抗相关性蛋白丢失性肠病的病例报告：胆囊水肿为重要线索
Yoshihiko Kakiuchi,Shinji Kuroda,Shunya Hanzawa et al.
Yoshihiko Kakiuchi et al.
We report a rare case of protein-losing enteropathy (PLE) during zolbetuximab treatment in a 73-year-old woman with Stage IVB gastric cancer. After chemo-immunotherapy and curative surgery, 3rd-line treatment with capecitabine, oxaliplatin,...
Type 2 diabetes in patients undergoing gastric cancer surgery: areas requiring disease-specific glycemic management [0.03%]
胃癌手术患者的2型糖尿病：需要针对性血糖管理的领域
Jimin Choi,Sungsoo Park,Yeongkeun Kwon
Jimin Choi
This review provides a comprehensive analysis of phase-specific management strategies for type 2 diabetes (T2D) in patients undergoing gastric cancer (GC) surgery, encompassing the preoperative, intraoperative and postoperative phases withi...